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ABSTRACT
Objective: The objective was to investigate changes in milk composition that reflect varia-
tions in breast permeability, milk synthesis, and immune response in women before, during,
and after mastitis
Methods: Mothers (n   26) were followed prospectively from day 5 postpartum to the end
of their lactation. Milk from each breast, blood, 24-hour urine samples, and data on breast
and systemic pathologies were collected at reference intervals during the first 3 months post-
partum, daily during the occurrence of any breast inflammation, and 7 days after resolution
of symptoms, and was analyzed using mixed-model analysis (repeated measures).
Results: There was a significant difference in sodium (p   0.001), chloride (p   0.001), serum
albumin (p   0.02) and lactose (p   0.003) in the breast with mastitis when compared with
both the contralateral asymptomatic breast and “healthy” breasts. Inflammation of the whole
breast was a significant predictor for a decreased glucose (p   0.01) and hyperacute systemic
symptoms predicted a decrease in milk glucose (p   0.03) and an increased lactoferrin (p  
0.05) and sIgA (p   0.03).
Conclusions: There is an increased breast permeability, reduced milk synthesis, and in-
creased concentration of the immune components sIgA and lactoferrin with increasing sever-
ity of breast and systemic symptoms. The changes observed in milk composition during pe-
riods of increased breast permeability cannot be solely explained by the current theory of
permeability of the paracellular pathway and further research in this area is required.
INTRODUCTION
I
NFLAMMATION OF THE BREAST during lactation
is experienced in varying degrees of severity
ranging from mild transient symptoms of in-
flammation, or blockage of the breast, to mas-
titis that is generally characterized by a more
severe illness accompanied by systemic symp-
toms.1 Approximately one in five women can
expect to suffer at least one episode during
their lactation,1–5 yet there is little understand-
ing of the physiologic and pathologic processes
occurring before, during, and after mastitis.
Changes previously observed in the bio-
chemical composition in milk from breasts with
mastitis include increases in the concentrations
of sodium,6–11 sodium potassium ratio,11 chlo-
ride,8 serum albumin,8,10 immune compo-
nents,9 and cytokines,11,12 along with a de-
crease in lactose,6–9 and glucose.8 It is not
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2School of Biomedical, Biomolecular, and Chemical Sciences, The University of Western Australia, Crawley, West-
ern Australia, Australia.known if these changes occur in the presence
of all the varying clinical forms of mastitis or
to what degree the natural course of change
and recovery occurs.
The aim of this study was to observe women
before, during, and after the occurrence of mas-
titis to describe changes in milk composition
that reflect variations in breast permeability,
milk synthesis, and immune response.
MATERIALS AND METHODS
Sample collection, recruitment, and demo-
graphics of subjects have been reported in de-
tail elsewhere;13 however, in brief: The research
conducted used a convenience sample of lac-
tating women (n   26), assessed to be at risk
for developing mastitis, who were then fol-
lowed prospectively from the fifth day post-
partum to the end of their lactation. Reference
samples of blood and milk were collected from
women at intervals during the first 3 months
postpartum to obtain data on the normal range
of a set of potential biochemical markers for
mastitis. Included in this range of markers were
sodium (Na), chloride (Cl), lactose, glucose,
serum albumin, lactoferrin, and secretory im-
munoglobulin A (sIgA) in milk and lactose in
blood and urine. C-reactive protein (CRP) in
milk and blood also was measured on days 5
and 14 postpartum. Women were interviewed
at collection times to identify any coexisting
breast (e.g., nipple trauma) or systemic
pathologies. If women suffered with mastitis at
any time during their lactation, further samples
were collected daily during the course of their
mastitis and at follow-up 7 days after resolu-
tion of symptoms. Women with mastitis com-
pleted a symptom log to provide descriptive
data on the characteristics and management
surrounding the onset and duration of their
mastitis.
The study was approved by The University
of Western Australia, Human Research Ethics
Committee.
Operational definitions
Breast inflammation. Breast inflammation was
defined as a warm to hot, red, and tender/
painful area of the breast. It was further cate-
gorized as localized, segmental, or total breast
inflammation according to the area of inflam-
mation present.
Systemic symptoms. Systemic symptoms were
defined as mild (feels unwell, tires easily,
afebrile [body temperature (T°)  37.5°C]);
acute (unwell, T°  37.4°C and  38.5°C, myal-
gia, needs to go to bed); and hyperacute (T°
 38.4°C, myalgia, headache or vomiting, rig-
ors).
The symptoms experienced were then used
to apply the following diagnostic criteria.
Blocked ducts were defined as tenderness, ery-
thema, and/or nodular area(s) of the breast
present for less than 24 hours and without ac-
companying systemic symptoms.
Mastitis is defined as any inflammation of
the breast present for more than 24 hours, and
accompanied by any degree of systemic illness.
Biochemical analysis
Methods for the biochemical analysis con-
ducted in this study along with recoveries and
coefficients of variance (excluding sIgA and
lactoferrin) have been reported by the authors
in detail.13 However, briefly: All analysis in
milk was undertaken on samples that were de-
fatted after collection (except chloride) and
then stored at  20°C until analysis. The con-
centration of lactose and glucose in milk was
determined by spectrophotometric assay14 and
lactose in urine and blood by bioluminescent
assays.15
The enzyme-linked immunosorbent assay
(ELISA) for serum albumin in milk was
adapted from the method of Schwerer et al.16
and is outlined in Cregan et al.17 Determina-
tion of the sodium concentration in defatted
milk samples was undertaken using a Corning
435 Flame Photometer® (Essex, UK) and chlo-
ride concentration in whole milk was deter-
mined using a combination chloride ion elec-
trode (ORION Model 96-17B®) and a direct
concentration read out specific meter (ORION
490A ®).
Measurement of sIgA and lactoferrin was
undertaken using ELISA.18 The recovery of a
known amount of sIgA and lactoferrin added
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96.7   5.9% (n   5), respectively. The interas-
say coefficients of variation were 3.8% (n   10)
and 4.9% (n   10), respectively.
Statistical analysis
Descriptive statistics used means and stan-
dard deviations or medians and interquartile
ranges, as appropriate, depending on normal-
ity. Hypothesis testing of all outcome measures
was based on analysis of variance with re-
peated measures within a mixed model. Mod-
els were used where individual women were
treated as random effects and comparison
groups (e.g., mastitis/no mastitis) as fixed ef-
fects.
In the analysis of outcomes that occurred at
various stages of lactation, appropriate adjust-
ments were made, using stage of lactation (day
postpartum) as one of the covariates in analy-
sis of variance models. Estimate effects were
presented as means and 95% confidence inter-
vals (95% CI). Any p-values   0.05 were con-
sidered significant. All data were analyzed us-
ing the mixed model module in SPSS 11.0 for
Mac OSX.
RESULTS
Biochemical composition of milk from 
“healthy” breasts
Breast milk samples were collected at five
reference time points, on days 5, 14, 30, 60, and
90 postpartum, and analyzed for composition
of lactose, glucose, sodium, chloride, serum al-
bumin, sIgA, and lactoferrin. Sample numbers
varied at each collection time point because
some mothers provided limited participation
and others suffered mastitis or other breast
symptoms at the time of collection; therefore
excluding them from the “healthy breast” sam-
ple.
Mixed model analysis, adjusted for the pres-
ence of any breast symptoms and stage of lac-
tation, showed no significant difference be-
tween concentrations of milk components in
the right and left breasts for sodium (p   0.29;
df:1,184; F   1.1), chloride (p   0.15; df:1,184;
F   2.1), glucose (p   0.26; df:1,184; F   1.3)
lactose (p   0.54; df:1,181; F   0.4), serum al-
bumin (p   0.140; df:1,110; F   2.2), lactoferrin
(p   0.51; df:1,182; F   0.4), and sIgA (p   0.75;
df:1,182; F   0.1). The combined results for
“healthy” left and right breasts at each refer-
ence collection time point are shown in Table 1.
Changes in milk composition associated with
events other than mastitis
Variation from the cohort’s normal milk
composition was observed in both women with
breast symptoms other than mastitis and
women with no breast symptoms. There was a
marked increase in sodium and chloride and a
decrease in lactose in milk in asymptomatic
breasts at days 5 and 14. These changes were
observed in women with birth at or before 38
weeks gestation (n   4), Cesarean birth (n   3),
and increased CRP in blood above the normal
mean for that time postpartum (n   5). Women
identified with low supply (n   1), self-per-
ceived oversupply (n   3), and nipple trauma
(n   7); all showed an association with an in-
crease in milk sodium (p   0.001;  p   0.001,
and p   0.004, respectively) and a decrease in
milk lactose (p   0.05; p   0.015; and p   0.001,
respectively). Changes also were observed in
the concentrations of chloride, glucose, lacto-
ferrin, and sIgA in milk, as well as the 24-hour
excretion of lactose in urine (Table 2).
Incidence of mastitis in the “at-risk” sample
Applying the operational definitions previ-
ously outlined, 14 of the 26 at-risk mothers suf-
fered a total of 22 episodes of mastitis (includ-
ing two bilateral). Range of occurrence was day
5 to day 400 postpartum, median day 49 (20,
187). Seven mothers experienced 13 episodes of
blocked duct(s) with range of occurrence from
days 14 to 310, median 60 (25, 102).
Blocked duct(s)
One mother (M8), who had undetectable
concentrations of sIgA in her breast milk and
was subsequently diagnosed with IgA defi-
ciency during the course of the study, contrib-
uted over 50% of episodes of blocked duct(s)
(n   7). Her data were omitted from the anal-
ysis and will be reported elsewhere. The re-
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each of blocked duct(s), and although milk
composition in the affected breast was variable,
the median was within normal range (Table 3),
as was median lactose excretion/24 hours at 3.0
(2.2, 5.1) mmol/24 hours. Variability in milk
composition was noted to be associated with
three mothers who had coexisting symp-
toms of nipple trauma (n   2) and oversupply
(n   1).
Mastitis symptoms
At the onset of mastitis 71% (n   17) of
breasts affected (n   24) presented with seg-
mental inflammation, 13% (n   4) with local-
ized inflammation, and 11% (n   3) with in-
flammation of the whole breast.
Duration of mastitis episodes ranged from 1
to 5 days, with a median of 2 days (1, 3). Breast
symptoms for mastitis episodes ranged from 1
to 5 days (2.2   1.1), whereas duration for sys-
temic symptoms was from 1 to 4 days (2.0  
1). At the onset of mastitis episodes, 38% (n  
8) of mothers suffered mild systemic symp-
toms, 38% (n   8) acute symptoms, and 28%
(n   6) hyperacute symptoms.
The severity of both systemic and breast
symptoms was greatest at the commencement
of the mastitis episode and decreased with
time. The severity of breast inflammation did
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TABLE 1. REFERENCE VALUES FOR BREAST MILK FROM “HEALTHY” RIGHT AND LEFT BREASTS COMBINED (N)
COLLECTED AT REFERENCE TIME POINTS DURING THE FIRST 3 MONTHS POSTPARTUM
Milk Day 5 Day 14 Day 30 Day 60 Day 90
component (n   26) (n   25) (n   32) (n   33) (n   40)
Lactose 164   21.2 171   19.6 178   18.2 175   16 175   18.8
(mmol/L)
Glucose 1.27   0.68 1.4   0.47 1.67   0.46 1.7   0.51 1.6   0.54
(mmol/L)
Sodium 21.4   8.0 13.4   4.8 12.6   2.3 13.3   4.9 12.6   4.3
(mmol/L)
Chloride 31.2   8.6 21.1   3.4 18.5   3.7 19.7   5.6 19.9   5.3
(mmol/L)
sIgA (g/L) 1.65   0.55 1.3   0.54 1.0   0.4 1.0   0.38 1.1   0.5
Lactoferrin 5.8   2.8 3.8   2.9 2.9   1.8 2.2   1.2 2.6   1.2
(g/L)
Serum 0.51   0.72 0.52   0.19 0.51   0.20 0.35   0.01 0.35   0.14
albumin (g/L)
Urinary 4.9   3.2 3.4   1.1 2.9   1.15 2.85   1.67 2.65   1.46
lactose (n   13) (n   12) (n   16) (n   16) (n   20)
excretion
(mmol/
24 hours)
TABLE 2. INDICATORS FOR CHANGES IN MILK COMPOSITION DURING THE FIRST THREE MONTHS POSTPARTUM
Excretion of
Breast lactose in
condition Sodium Chloride Lactose Glucose Lactoferrin sIgA urine/24 h
Nipple Increased Increased Decreased Decreased Decreased Increased Increased
trauma (p   0.004) N/S (p   0.001) (p   0.031) N/S N/S N/S
(n   17)
Perceived Increased Increased Decreased Decreased Increased Increased Increased
oversupply (p   0.001) (p   0.001) (p   0.015) N/S (p   0.001) N/S (p   0.001)
(n   19)
Low supply Increased Increased Decreased Decreased Increased Increased Increased
(n   4) (p   0.001) (p   0.001) (p   0.05) (p   0.001) N/S (p   0.04) (p   0.034)
Adjusted for coexisting pathologies and stage of lactation. Abbreviations and symbols: n   number of samples;
N/S   not significant.not predict the severity of systemic symptoms
(p   0.23, df:2,71; F   1.5).
Changes in milk composition during mastitis
The mixed model analysis showed a signifi-
cant difference in the concentrations of sodium,
chloride, serum albumin, and lactose in the
breast with mastitis when compared with both
the contralateral asymptomatic breast and
“healthy” breasts from women without either
mastitis or coexisting breast symptoms (Table
3). Although there was a trend for a decrease
in glucose and an increase in lactoferrin and
sIgA in the mastitis breast, the difference was
not significant in the mastitis/no mastitis
model. The 24-hour urinary excretion of lactose
during mastitis has been reported in detail.13 It
was significantly higher during mastitis (p  
0.001; df:1,117; F   26.6), peaked at the com-
mencement of the mastitis at a median of 7.5
mmol/24 hours (6.3, 12.4), and decreased over
time until there was no significant difference at
the time of follow-up (7 days after resolution
of symptoms) when compared with the moth-
ers with no mastitis (p   0.25; df:1,48; F   1.3).
There were no significant differences in the
breast with mastitis at follow-up when com-
pared with “healthy” breasts for sodium (p  
0.12; df:1,168; F   2.4), chloride (p   0.16;
df:1,157; F   0.16), serum albumin (p   0.29;
df:1,173; F   1.1), lactose (p   0.16, df:1,153;
F   1.9), glucose (p   0.91; df:1,164; F   0.01),
lactoferrin (p   0.93; df: 1,157; F   0.006), and
sIgA (p   0.55; df:1,162; F   0.36). All analyses
were adjusted for coexisting symptoms and
stage of lactation.
Variation in milk composition changes 
during mastitis
Results from two mothers (M1 and M17) are
presented as outlier examples of the varying
course, and degree of change, in milk compo-
sition between individuals who experienced
similar severity and duration of symptoms. The
most extreme changes in milk composition
were experienced by M17 (see Table 4), who re-
ported oversupply problems in the weeks be-
fore suffering with mastitis. These results re-
flect the findings from the mixed models
analyses (see Table 3), with a return to normal
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TABLE 3. ESTIMATED MEAN (95% CI) FROM THE MIXED MODEL ANALYSIS FOR CONCENTRATION OF MILK COMPONENTS
IN THE MASTITIS BREAST COMPARED WITH THE CONTRALATERAL ASYMPTOMATIC
BREAST, “HEALTHY” ASYMPTOMATIC BREASTS, AND WOMEN WITH BLOCKED DUCT(S)
Statistical
analysis (mixed
Contralateral model mastitis/no Blocked No mastitis
asymptomatic mastitis) adjusted duct/s “healthy
breast for stage of breast breasts”
Mastitis breast estimated lactation and median estimated
Milk estimated mean mean coexisting (25, 75) mean
component (95% CI) (95% CI) pathologies (n   6) (95% CI)
Sodium 21.8 (16.8; 26.9) 14.8 (9.7, 20.0) p   0.001; df: 1,127; 13 (8, 18) 14 (12, 16)
(mmol/L) (n   80) (n   63) F   23.9 (n   155)
Chloride 30 (23.9, 36.8) 22 (15.7, 28.6) p   0.001; df: 1,127; 22 (19, 26) 21 (19, 23)
(mmol/L) (n   80) (n   63) F   23.6 (n   155)
Serum 0.74 (0.54, 0.92) 0.60 (0.41, 0.79) p   0.02; df: 1,126; 0.5 (0.4, 0.8) 0.5 (0.36, 0)
albumin (n   79) (n   62) F   5.6 (n   154)
(g/L)
Lactose 159 (151, 166) 168 (161, 175) p   0.003; df: 1,128; 170 (158, 189) 174 (169, 1)
(mmol/L) (n   80) (n   63) F   8.9 (n   155)
Glucose 1.39 (1.1, 1.69) 1.5 (1.2, 1.8) p   0.21; df: 1,126; 1.5 (1.3, 2) 1.6 (1.4, 1)
(mmol/L) (n   79) (n   62) F   1.6 (n   154)
Lactoferrin 3.45 (2.2, 4.7) 2.68 (1.41, 3.95) p   0.069; df: 1,128; 2.4 (1.2, 3.4) 3.2 (2.5, 
(g/L) (n   79) (n   62) F   3.4 (n   155)
sIgA (g/L) 1.22 (1.02, 1.43) 1.19 (0.99, 1.4) p   0.068; df: 1,127; 1.2 (0.8, 1.6) 1.25 (1.1, 1
(n   79) (n   62) F   0.164 (n   154)concentrations at follow-up with the exception
of serum albumin and lactoferrin, which were
both increased in comparison with reference
day 30 results from “healthy” breasts. The ex-
cretion of lactose on day 1 of the episode was
very elevated at 12.5 mmol/24 hours compared
with her reference day 90 sample, which was
within normal range at 2.2 mmol/24 hours. In
contrast M1, who had a history of mastitis, ex-
perienced minor changes in milk composition
at the onset of symptoms followed by an
overnight recovery of the concentrations of so-
dium, chloride, lactose, and serum albumin to
within normal range despite going on to expe-
rience symptoms for another 3 days.
Changes in milk composition in relation to
severity of symptoms
Mixed model analyses were undertaken to
examine whether either the severity of breast
symptoms (localized, segmental, or whole
breast inflammation) or the severity of systemic
symptoms (nil, mild, acute, or hyperacute)
could predict changes in milk composition.
Although the concentration of sodium and
chloride in the breast with mastitis increased
according to severity of symptoms suffered, the
differences were not significant.
Acute systemic symptoms predicted a sig-
nificant decrease in milk lactose (p   0.037;
df:3,69; F   2.9) compared with patients in
whom systemic symptoms had resolved but
breast inflammation remained.
The statistical models showed inflammation
of the whole breast (p   0.01; df:2,65; F   5.0)
and hyperacute systemic symptoms (p   0.034;
df:3,69; F   3) were both significant predictors
for a decrease in milk glucose compared with
less acute symptoms (Fig. 1), where glucose re-
mained fairly stable.
Although lactoferrin and sIgA followed a
varied course, in regard to breast and systemic
symptoms, the concentration of both defense
components showed a trend toward increasing
with severity of symptoms experienced. There
was a marked increase in lactoferrin with the
more extreme symptoms of whole breast in-
flammation, and both lactoferrin (p   0.05;
df2,71; F   2.4) and sIgA (p   0.028; df:2,67;
F   3.9) were significantly increased with hy-
peracute systemic symptoms.
Sodium, chloride, lactose, and serum albu-
min remained increased even when mothers
had recovered from systemic symptoms but
still experienced breast inflammation.
Mixed model analyses showed that neither
milk composition at day 5 postpartum nor at
the reference sampling days before mastitis
could predict mastitis occurrence.
DISCUSSION
The prospective design used in this study has
enabled a detailed observation of breastfeeding
women before, during, and after their experi-
ence of mastitis. Recruiting breastfeeding
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TABLE 4. MILK COMPOSITION IN THE BREAST WITH MASTITIS OF M17 FOR EACH DAY OF HER MASTITIS EPISODE
WITH FOLLOW-UP COMPARED WITH THE DAY 30 REFERENCE RESULTS FROM “HEALTHY” BREASTS
Serum
M17/ Sodium Chloride Lactose Glucose albumin Lactoferrin sIgA
day postpartum (mmol/L) (mmol/L) (mmol/L) (mmol/L) (g/L) (g/L) (g/L)
day 61 77 100 82 1.54 2.54 3.2 0.81
day 62 50 71 135 1.51 2.25 2.3 1.07
day 63 27 55 175 1.54 2.0 2.1 0.9
Follow-up 9 18 184 1.3 1.28 4.8 1.2
day 70
Day 30 12   2 18.5   4 178   18 1.6   0.5 0.5   0.2 2.9   1.8 1.0   0.4
reference
results from
“healthy”
breastswomen with known risk factors for mastitis, in
particular women with a past history of masti-
tis and/or nipple trauma and attachment diffi-
culties in the early postpartum period, pro-
vided a very high incidence of mastitis with a
wide range of severity of symptoms. Subse-
quently, this proved an efficient method for the
prospective observation of women who de-
velop mastitis during lactation. It also demon-
strated the importance of counseling mothers
with known risk factors for mastitis in strate-
gies that can be undertaken to prevent this sig-
nificant problem.
Although the results for milk composition
from healthy breasts in the first 3 months post-
partum have been controlled for any breast-
feeding disorders, detectable through exami-
nation and interview, there are some marked
differences in concentrations in some milk
components compared with previously pub-
lished findings.19,20 Despite the general trends
being similar, lactose concentrations at all ref-
erence time points within the first 3 months
postpartum were lower, and conversely so-
dium and chloride concentrations were higher.
The relatively low stable excretion rate for uri-
nary lactose indicates that these variations are
not a result of increased paracellular pathway
permeability. This suggests that the higher than
normal concentrations of milk sodium and
chloride observed in “healthy breasts” may be
a normal physiologic response to a lower con-
centration of lactose, ensuring that the osmo-
lality of milk remains isotonic with blood. This
has important implications for the assumption
that a raised sodium concentration is a result
of subclinical mastitis.
The term subclinical mastitis has been ap-
plied to lactating women who present with in-
creased sodium after day 3 postpartum in the
absence of weaning.21 However, this definition
may obscure other potential causative factors.
The authors’ study identified other factors that
may be associated with changes in the concen-
tration of sodium and other milk components
over the first 3 months postpartum, such as:
preterm birth, nipple trauma, self-perceived
oversupply, low supply, and an increased
acute phase response (raised CRP). The latter
supports other findings, in which an increase
in the Na/K ratio in milk from both breasts was
observed in women with systemic infection.22
The small sample of women diagnosed with
blocked duct(s), showed no significant change
FETHERSTON ET AL. 142
2
1.5
1
breast symptoms
0.5
0
m
i
l
k
 
g
l
u
c
o
s
e
 
(
m
m
o
l
/
L
)
n
o
 
m
a
s
t
i
t
i
s
 
( n
 
=
 
1
5
4
)
c
o
n
t
r
a
l
a
t
e
r
a
l
 
b
r
e
a
s
t
 
( n
 
=
 
6
2
)
l
o
c
a
l
i
z
e
d
 
( n
 
=
 
3
2
)
s
e
g
m
e
n
t
a
l
 
( n
 
=
 
3
6
)
w
h
o
l
e
 
b
r
e
a
s
t
 
( n
 
=
 
8
)
f
o
l
l
o
w
-
u
p
 
( n
 
=
 
1
4
)
2
1.5
1
systemic symptoms
0.5
0
m
i
l
k
 
g
l
u
c
o
s
e
 
(
m
m
o
l
/
L
)
n
o
 
m
a
s
t
i
t
i
s
 
( n
 
=
 
1
5
4
)
n
o
 
s
y
m
p
t
o
m
s
 
( n
 
=
 
1
9
)
m
i
l
d
 
( n
 
=
 
3
4
)
a
c
u
t
e
 
( n
 
=
 
1
6
)
h
y
p
e
r
a
c
u
t
e
 
( n
 
=
 
1
0
)
A B
FIG. 1. The statistical models showed inflammation of the whole breast (A) and hyperacute systemic symptoms (B),
were both significant predictors for a decrease in milk glucose compared with less acute symptoms, where glucose
remained fairly stable.in milk composition, although there was a wide
variation in some milk components. This is in
contrast to breast inflammation that lasted
longer than 24 hours and was accompanied by
systemic symptoms (defined as mastitis), in
which significant changes in sodium, chloride,
lactose, and serum albumin in milk were ob-
served. The apparent transitory nature and lack
of significant change in milk composition dur-
ing blocked duct(s) is reassuring, particularly
as this is a very commonly reported problem
among breastfeeding women.
The increase in the concentrations of sodium,
chloride, and serum albumin and the decrease
in lactose in the milk from the breast with mas-
titis is similar to that found in other studies.6–11
The 24-hour excretion of lactose in urine also
was significantly increased, confirming that
these changes were likely to have occurred as
a result of an increase in the permeability of the
paracellular pathway. However, concentra-
tions of glucose and serum albumin in milk re-
mained raised even after sodium, chloride, and
lactose had returned to normal, suggesting that
the changes in milk composition were more
complex than is currently explained by the in-
creased permeability of the paracellular path-
way breast model during mastitis. Also, the
concentration of glucose in breast milk re-
mained low at lactogenesis II (day 5) and sta-
ble during mastitis, except during severe symp-
toms, even in the presence of extreme changes
in sodium, chloride, and lactose (see Tables 3
and 4). This raises many questions about the
biological structure of the tight junctions within
the breast and changes that might occur in re-
sponse to pathology.
Although there were no significant changes
in the general mastitis/no mastitis models for
glucose, lactoferrin, and sIgA, the models dif-
ferentiating between the degree of severity of
inflammation and systemic symptoms were
significantly predictive as severity of symp-
toms increased. The significant decrease in 
concentration of glucose during whole breast
inflammation and hyperacute systemic symp-
toms indicates an inhibition of glucose uptake
into the cell, rapid depletion because of in-
creased metabolism resulting from loss of lac-
tose, or both. The percentage of lactose excreted
in urine did not account for the decrease in lac-
tose concentration within the breast.13 There-
fore, it is concluded that in addition to loss of
lactose through the paracellular pathway there
also was a decrease in lactose synthesis. This
may result from both the decrease in available
glucose, especially during extreme symptoms,
and damage or death of lactocytes because of
inflammation.
The significant increases in the concentra-
tions of sIgA and lactoferrin only in the pres-
ence of whole breast and hyperacute systemic
symptoms may partially explain the varied
findings from different researchers about lacto-
ferrin during mastitis. Buescher and Hair12 did
not find an increase in lactoferrin in milk dur-
ing mastitis despite an increase in TNF-  con-
centrations. This is contrary to a report11 of in-
creased lactoferrin concentrations in women
with mastitis (1.23 g/L) compared with women
without mastitis (0.56 g/L). However, the con-
centrations reported in this study11 during
mastitis were not higher than the concentra-
tions observed in the “healthy” cohort from the
authors’ study (2.9 g/L), the pooled results
from Jensen19 (1.65 to 1.94 g/L), or results from
The Gambia9 (1.87 g/L). The concentration of
lactoferrin in milk appears quite variable, sug-
gesting it may not be a reliable marker for mas-
titis.
Previous research has observed changes in
the contralateral asymptomatic breast sugges-
tive of subclinical inflammatory changes.10 De-
spite an increased variation around the mean
similar to the changes seen in the breast with
mastitis, when controlled for stage of lactation
and other coexisting pathologies, this study
found no significant differences in the con-
tralateral asymptomatic breast when compared
with “healthy” breasts.
Milk from the breast with mastitis was ana-
lyzed at follow-up 7 days after the resolution of
symptoms, and found to have returned to
within normal range for most mothers. This con-
firms that the breast affected by mastitis made
a rapid return to normal function in most cases,
and supports other findings9 that there was no
significant difference in the breast with mastitis
compared with the unaffected breast at follow-
up of 5 weeks after initial presentation.
Milk composition has been found to be a pre-
disposing factor for mastitis, with a lower con-
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women who developed mastitis in The Gam-
bia.9 Although no significant predictors in milk
composition were identified either at day 5 or
at the sample collected before the occurrence of
mastitis, it is of interest that the mother with
no sIgA in her milk suffered with recurrent
episodes of transient localized breast inflam-
mation and apparent blockage.
CONCLUSION
Changes in milk composition observed in
this study indicate there is an increased breast
permeability, reduced milk synthesis, and in-
creased concentration of the immune compo-
nents sIgA and lactoferrin with increasing
severity of breast and systemic symptoms. The
changes observed in milk composition during
periods of increased breast permeability can-
not be solely explained by the current theory
of permeability of the paracellular pathway,
and further research in this area is required.
Despite the acute illness and degree of breast
inflammation often associated with mastitis, it
is remarkable to find that the changes observed
in milk composition are only temporary, and
in most cases recovery of the breast to its nor-
mal state is achieved within 1 week of the res-
olution of mastitis symptoms.
As there appears to be a wide range of fac-
tors that might influence changes in some milk
components, it is important that a mother’s
health status, and in particular breast health,
should be taken into consideration when es-
tablishing a normal range for breast milk com-
position. A better understanding of how breast
and systemic pathologies affect milk composi-
tion and breast physiology will be gained if a
possible causative association for breast milk
changes are further investigated and defined.
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